Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. 2004D-0414]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

The Food and Drug Administration (FDA) is announcing the availability of a document entitled “Guidance for Industry:  FDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information,” dated September 2004.  The guidance document provides to vaccine manufacturers, medical practitioners, and consumers an overview of the vaccine labeling review process, a description of FDA's review of childhood vaccine labeling, and a discussion of the type of data FDA examines when determining the adequacy of vaccine labeling.

# DATES:

Submit written or electronic comments on agency guidances at any time.

# ADDRESSES:

                        Submit written requests for single copies of the guidance to the Office of Communication, Training, and Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448.  Send one self-addressed adhesive label to assist the office in processing your requests.  The guidance may also be obtained by mail by calling the CBER Voice Information System at 1-800-835-4709 or 301-827-1800.  See the                         **SUPPLEMENTARY INFORMATION**                         section for electronic access to the guidance document.                    

                    Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD  20852.  Submit electronic comments to                     *http://www.fda.gov/​dockets/​ecomments*.                

# FOR FURTHER INFORMATION CONTACT:

Astrid Szeto,   Center for Biologics Evaluation and Research (HFM-17),   Food and Drug Administration, suite 200N, 1401 Rockville Pike, Rockville, MD  20852-1448, 301-827-6210.

# SUPPLEMENTARY INFORMATION:

## I.  Background

FDA is announcing the availability of a document entitled “Guidance for Industry:  FDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information,” dated September 2004.  The guidance document provides to vaccine manufacturers, medical practitioners, and consumers an overview of the vaccine labeling review process, a description of FDA's review of childhood vaccine labeling under section 314 of the National Childhood Vaccine Injury Act (NCVIA), and a discussion of the type of data FDA examines when determining the adequacy of vaccine labeling.  The processes described represent current FDA practices and do not represent any new interpretation of existing labeling statutes, regulations, or guidances.

The guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115).  The guidance represents the agency's current thinking on this topic.  It does not create or confer any rights for or on any person and does not operate to bind FDA or the public.  An alternative approach may be used if such approach satisfies the requirement of the applicable statutes and regulations.

## II. Comments

                    In accordance with 21 CFR 10.115(g)(4)(i), FDA is immediately implementing this guidance.  Interested persons may, at any time, submit written or electronic comments to the Division of Dockets Management (see                     **ADDRESSES**                    ) regarding this guidance.  Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy.  Comments are to be identified with the docket number found in the brackets in the heading of this document.  A copy of the guidance and received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.                

## III. Electronic Access

                    Persons with access to the Internet may obtain the guidance at either                     *http://www.fda.gov/​cber/​guidelines.htm*                     or                     *http://www.fda.gov/​ohrms/​dockets/​default.htm*.                

Dated: September 20, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 04-22213 Filed 10-1-04; 8:45 am]

BILLING CODE 4160-01-S